82688
document
Neuroendocrine effects of sumatriptan . The neuroendocrine effects of the 5-HT receptor agonist , sumatriptan ( 6 mg subcutaneously ) , were studied in 11 healthy male subjects using a placebo-controlled , cross-over design . Compared to placebo , sumatriptan significantly lowered levels of plasma prolactin but increased those of plasma growth hormone . There was no effect on plasma cortisol concentrations . The neuroendocrine effects of sumatriptan differ from those of previously described 5-HT-receptor agonists , and may be a consequence of selective activation of 5-HT1D or 5-HT1B receptors . However , the present data can not exclude the possibility that the neuroendocrine changes reflect nonspecific stress responses or changes in pituitary blood flow .
82689
Intervention_Pharmacological
sumatriptan
82690
Intervention_Pharmacological
sumatriptan ( 6 mg subcutaneously )
82691
Intervention_Control
placebo-controlled
82692
Intervention_Control
placebo
82693
Intervention_Pharmacological
sumatriptan
82694
Intervention_Pharmacological
sumatriptan
82695
Outcome_Physical
Neuroendocrine effects
82696
Outcome_Physical
plasma prolactin
82697
Outcome_Physical
plasma growth hormone .
82698
Outcome_Physical
plasma cortisol concentrations .
82699
Participant_Condition
11 healthy male subjects